Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • Histobiolab Provides Over 150 Fish Probes to Satisfy Precise Biological Research Needs

    Nov 1, 2022, 10:05 AM by
    Full story
  • Creative Bioarray Provides 3D Cell Patterning Service Based to Speed up Drug Screening

    Nov 1, 2022, 10:04 AM by
    Full story
  • Oxford Nanopore Launches Epic Sequencer, 10x Genomics Partnership

    Nov 1, 2022, 01:00 AM by User Not Found
    Bio-IT World | It’s been a big month for sequencing news. Last week, Oxford Nanopore announced the PromethION 2 (“P2”) Solo sequencer and a new collaboration with 10X Genomics to enable a streamlined workflow for sequencing full-length transcripts in single reads.
    Full story
  • PubHive Upgrades SaaS Platform to MedDRA Version 25.1

    Oct 31, 2022, 17:33 PM by
    Drug safety and pharmacovigilance (DSPV) teams that license access to the PubHive Navigator platform can now access the newest MedDRA version when performing signal evaluation and reporting activities
    Full story
  • Terumo Pharmaceutical Solutions expands CDMO services outside Japan for global market

    Oct 31, 2022, 17:33 PM by
    Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of injection, primary container, and infusion therapy devices, has today announced it will expand its contract development and manufacturing services for parenteral drugs to global customers.
    Full story
  • MULTI-LEVEL & MULTI-ANALYTE LIQUID STABLE CLINICAL ENZYME CALIBRATION VERIFIERS AVAILABLE FROM VERICHEM

    Oct 31, 2022, 17:32 PM by
    Full story
  • CARLSBAD, Calif. (Oct. 31, 2022) – Thermo Fisher Scientific introduces new dPCR wastewater surveillance kit and RNA master mix to simplify detection of SARS-CoV-2 targets

    Oct 31, 2022, 17:31 PM by
    Full story
  • New NoriZite™ Nasal Spray launches in the UK

    Oct 28, 2022, 09:37 AM by
    Birmingham Biotech LTD, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, today announces that NoriZite™ Nasal Spray, an easy-to-use nasal device designed to block and trap inhaled virus particles, is now available to buy in the UK.
    Full story
  • Samsung Biologics Reports Third Quarter 2022 Financial Results

    Oct 28, 2022, 09:36 AM by
    Samsung Biologics reports third quarter 2022 financial results
    Full story
  • Abundent Application Potentials of Nanomaterials

    Oct 28, 2022, 09:34 AM by
    Full story
  • Alfa Chemistry Announces Offering of Low Molecular Weight Carboxylic Acids

    Oct 28, 2022, 09:33 AM by
    Full story
  • CD Formulation: One-Stop Pharmaceutical Formulation Solution Makes Drug Development Faster, Easier and More Cost-Effective

    Oct 27, 2022, 10:12 AM by
    Full story
  • AtlantiCare Implements Orbita’s Healthcare Virtual Assistants to Enhance Access to Care

    Oct 27, 2022, 10:11 AM by
    Full story
  • Andelyn Biosciences announces opening of its state-of-the-art GMP manufacturing facility to meet industry demand

    Oct 27, 2022, 10:09 AM by
    Contact information Eric Blair, Chief Commercial Officer Eric.Blair@AndelynBio.com For media enquiries, please contact Imogen Quail, PR Manager, imogen.quail@ramarketingpr.com, ramarketingpr.com About Andelyn Biosciences, Inc. Andelyn is a biopharmaceutical CDMO Pioneering Solutions That Turn Hope into Reality™. Headquartered in the greater Columbus, Ohio, USA area, Andelyn’s capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP drug substance manufacturing up to 2000L, and drug product manufacturing services. Having 20+ years of experience in viral vector manufacturing, Andelyn offers its clients direct access to globally recognized thought leaders that have enabled 75+ worldwide clinical trials. With the experience gained from over 400 cGMP clinical batches and 2000+ research-grade productions, Andelyn provides its clients with end-to-end manufacturing services, advanced quality systems, full regulatory support, and supply chain vertical integration. Andelyn began operations in its state-of-the-art 200,000 sq. ft. commercial manufacturing facility in September 2022, expanding capacity across 14+ production suites for customization of new programs and tech transferred programs. Andelyn is one of a few select CDMOs that offer clinical through commercial-scale capabilities that will help fulfil Andelyn’s mission of accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients. Andelyn is owned and supported by Nationwide Children’s Hospital (NCH) and Pall-Cytiva, part of Danaher Corporation.
    Full story
  • The American Heart Association Launches Precision Medicine Platform, New Proprietary Computational Models for Oncology Drug Discovery, More

    Oct 27, 2022, 01:00 AM by User Not Found
    Bio-IT World | New consensus recommendations for using in silico approaches to validate next-generation sequencing data analysis pipelines; a pre-consortium collaboration for medical product development in alpha-1 antitrypsin deficiency; integrated drug discovery services to design, synthesize, and profile targeted heterobifunctional protein degraders; and more.
    Full story
  • Conclusions of the 7th Crystal Structure Prediction Blind Test

    Oct 26, 2022, 10:04 AM by
    • Seven structures of 2D systems that had been experimentally analysed but not published (‘blind’) released to participants along with some experimental conditions. • Boundaries pushed beyond the pharmaceutical sector to areas such as electronics and photonics with the inclusion of an optoelectronic system containing silicon and a metal-organic system containing copper. • Also included one of the most challenging systems in CSP Blind Test history - a large, highly polymorphic, phamaceutical drug candidate. • Test ran from October 2020 to September 2022. • More experimental data released over the course of the test to simulate real world conditions. • Submissions received from industrial and academic groups worldwide. • All compounds successfully had their experimentally observed crystal structures predicted from landscapes of 1K+ potential structures. • PXRD challenge showcased the application of CSP to industrially relevant molecules.
    Full story
  • Inizio commits to helping limit the impact of climate change and achieving SBTi Net-Zero Standard

    Oct 26, 2022, 10:03 AM by
    Inizio commits to SBTi Net-Zero Standard
    Full story
  • Leading Enterprise Search Provider for Life Sciences Sector Appoints new CMO

    Oct 26, 2022, 10:03 AM by
    Enterprise search provider Sinequa announced the appointment of Wendy Lurrie as its new Chief Marketing Officer. Sinequa works with some of the leading brands in pharma and life sciences including: Pfizer, GSK, Takeda, Astellas, AstraZeneca, UCB and others. As Sinequa’s new CMO, Wendy will help extend Sinequa’s global marketing and brand strategy for the important bio and life sciences sector, and support the company’s ongoing expansion of its North American presence.
    Full story
  • CD BioGlyco Constructures a Glycoengineered P. pastoris Expression System for Research Use

    Oct 26, 2022, 10:02 AM by
    Full story
  • The Long and Short of It: PacBio Gives Updates on Separate New Long-Read, Short-Read Platforms

    Oct 26, 2022, 09:22 AM by User Not Found
    Bio-IT World | At the American Society of Human Genetics meeting last night, Pacific Biosciences planned to host a “celebration of genomics.” Among the announcements, PacBio will give updates on its two new sequencing platforms: the Onso Sequencing System and the Revio long-read sequencing system, for which the company began taking orders last night.
    Full story
  • «
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118 (current)
  • 119
  • 120
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy